Gilead Sciences Inc. and privately held GlobeImmune Inc. turned up the heat on an already sizzling hepatitis space by inking an exclusive worldwide license and collaboration to develop therapeutic vaccines that use Gilead's Viread (tenofovir disoproxil fumarate) and other oral therapies to treat chronic hepatitis B virus (HBV).